Piramal Pharma Limited annonce ses résultats consolidés pour le quatrième trimestre et l’exercice 2023

MUMBAI, Inde, 26 mai 2023 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a annoncé aujourd’hui ses résultats consolidés pour le quatrième trimestre (T4) et l’exercice clos le 31 mars 2023. Faits saillants des résultats financiers consolidés : (En crores INR) Détails Trimestriels Année complète T4 Exercice 2023 T4 Exercice 2022 Par rapport à l’année précédente Croissance … Read more

Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023

MUMBAI, India, May 24, 2023 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23 ended 31st March 2023. Consolidated Financial Highlights (In INR Crores) Particulars Quarterly Full Year Q4 FY23 Q4 FY22 YoYGrowth Q3 FY23 QoQGrowth FY23 FY22 YoYGrowth Revenue from … Read more

Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023

MUMBAI, India, May 24, 2023 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the fourth quarter (Q4) and full year FY23 ended 31st March 2023. Consolidated Financial Highlights (In INR Crores) Particulars Quarterly Full Year Q4 FY23 Q4 FY22 YoYGrowth Q3 FY23 QoQGrowth FY23 FY22 YoYGrowth Revenue from … Read more